Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 49.15 USD 1.89% Market Closed
Market Cap: 7.8B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

TECH Price Targets Summary
Bio-Techne Corp

Wall Street analysts forecast TECH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TECH is 82.74 USD with a low forecast of 51.51 USD and a high forecast of 99.75 USD.

TECH Lowest Forecast
Wall Street Target
51.51 USD
5% Upside
TECH Average Forecast
Wall Street Target
82.74 USD
68% Upside
TECH Highest Forecast
Wall Street Target
99.75 USD
103% Upside
Lowest
Price Target
51.51 USD
5% Upside
Average
Price Target
82.74 USD
68% Upside
Highest
Price Target
99.75 USD
103% Upside
Bio-Techne Corp Competitors:
Price Targets
BIO
Bio Rad Laboratories Inc
34% Upside
CDXS
Codexis Inc
203% Upside
S
237690
ST Pharm Co Ltd
63% Upside
TECN
Tecan Group AG
28% Upside
BIO
Bio Rad Laboratories Inc
34% Upside
CDXS
Codexis Inc
203% Upside
S
237690
ST Pharm Co Ltd
63% Upside
TECN
Tecan Group AG
28% Upside
STVN
Stevanato Group SpA
14% Upside
Q
QSI
Quantum-Si Inc
133% Upside
J
603127
Joinn Laboratories China Co Ltd
20% Upside
300404
Boji Medical Technology Co Ltd
45% Upside

Revenue
Forecast

Revenue Estimate
Bio-Techne Corp

For the last 8 years the compound annual growth rate for Bio-Techne Corp's revenue is 11%. The projected CAGR for the next 3 years is 8%.

11%
Past Growth
8%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Bio-Techne Corp

For the last 8 years the compound annual growth rate for Bio-Techne Corp's operating income is 6%. The projected CAGR for the next 3 years is 27%.

6%
Past Growth
27%
Estimated Growth
Estimates Accuracy
-30%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Bio-Techne Corp

For the last 8 years the compound annual growth rate for Bio-Techne Corp's net income is 6%. The projected CAGR for the next 3 years is 32%.

6%
Past Growth
32%
Estimated Growth
Estimates Accuracy
-29%
Average Miss
What are analyst estimates?

See Also

Summary
TECH intrinsic value, competitors valuation, and company profile.
DCF Valuation
TECH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TECH stock valuation using valuation multiples.
Wall Street Estimates
TECH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TECH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TECH's stock price target?
Price Target
82.74 USD

According to Wall Street analysts, the average 1-year price target for TECH is 82.74 USD with a low forecast of 51.51 USD and a high forecast of 99.75 USD.

What is Bio-Techne Corp's Revenue forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for Bio-Techne Corp's revenue is 11%. The projected CAGR for the next 3 years is 8%.

What is Bio-Techne Corp's Operating Income forecast?
Projected CAGR
27%

For the last 8 years the compound annual growth rate for Bio-Techne Corp's operating income is 6%. The projected CAGR for the next 3 years is 27%.

What is Bio-Techne Corp's Net Income forecast?
Projected CAGR
32%

For the last 8 years the compound annual growth rate for Bio-Techne Corp's net income is 6%. The projected CAGR for the next 3 years is 32%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 255,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.